TopoTarget A/S Symbion Fruebjergvej 3 DK 2100 Copenhagen Denmark Tel: +45 39 17 83 92 Fax: +45 39 17 94 92 CVR-nr: 25695771 www.topotarget.com Report pursuant to the Danish Securities Trading Act, Section 28a Copenhagen - 6 December 2007 - Pursuant to the Danish Securities Trading Act, Section 28a TopoTarget A/S (OMX: TOPO) is obliged to report on transactions by members of its senior management and their related parties in shares issued by TopoTarget A/S and related securities. Name Leif Hamø Reason CFO Issuer and ISIN code TopoTarget A/S, DK0060086072 Transaction Purchase Trade date 27 November 2007 Market Copenhagen Stock Exchange Number 10,000 Market value in DKK 209,000 TopoTarget A/S For further information, please contact: Dr. Peter Buhl Jensen Telephone +45 39 17 83 41 Chief Executive Officer Mobile +45 21 60 89 22 Background information About TopoTarget TopoTarget (OMX: TOPO) is a biotech company, headquartered in Denmark and with subsidiaries in the UK, Germany, Switzerland and the US, dedicated to finding ''Answers for Cancer'' and developing improved cancer therapies. TopoTarget is founded and run by clinical cancer specialists and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer. Focus lies on highly predictive cancer models and key cancer targets (including HDACi, NAD+, mTOR, FASligand and topoisomerase II inhibitors) and a strong development foundation has been built. TopoTarget has a broad portfolio of small molecule pre-clinical drug candidates and eight drugs (both small molecules and protein based) are in clinical development, including both novel anti-cancer therapeutics and new cancer indications for existing drugs. Savene™/Totect™ is TopoTarget's first product on the market. For more information, please refer to www.topotarget.com.